Advertisement

Topics

FDA Genetic Toxicology Workshop: How Many Doses of an DNA Reactive (Ames-positive) Drug can be Safely Administered to Healthy Subjects? - 11/04/2019 - 11/04/2019

14:28 EDT 12 Jul 2019 | FDA

The topic to be discussed is Healthy subjects receive no benefits from treatment with a DNA-reactive drug and could potentially be exposed to significant health risks.

Original Article: FDA Genetic Toxicology Workshop: How Many Doses of an DNA Reactive (Ames-positive) Drug can be Safely Administered to Healthy Subjects? - 11/04/2019 - 11/04/2019

NEXT ARTICLE

More From BioPortfolio on "FDA Genetic Toxicology Workshop: How Many Doses of an DNA Reactive (Ames-positive) Drug can be Safely Administered to Healthy Subjects? - 11/04/2019 - 11/04/2019"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Bioinformatics
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...